A new report from IMARC Group expects that as a result of an avalanche of patent expiries and a thin pipeline, sales worth US$ 8.7 Billion will be eroded from the US cholesterol lowering agent market.
By : |
08-06-2011
|
Health and Fitness:Health and Fitness
| Total Views :
671